A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2006
11/29/2006	CN1868543A Biodegradable high molecular gel medicine composition, its prepn. method and use thereof
11/29/2006	CN1868541A Chitin nanometer granule for programmable releasing various kinds of medicine, and its prepn. method
11/29/2006	CN1868540A Mixture prepn. and its application
11/29/2006	CN1868539A Mixture prepn. and its application
11/29/2006	CN1868480A Methods for inhibiting cognitive deterioration in adults with down's syndrome
11/29/2006	CN1868458A Controlled release composition and method of producing the same
11/29/2006	CN1868454A Slow-release injection contg. platinum compounds and its potentiator
11/29/2006	CN1868453A Slow-release injection contg. platinum compounds and cellulotoxic medicines
11/29/2006	CN1868452A Anticancer slow-release injection contg. platinum compounds
11/29/2006	CN1868420A Human soft tissue filler for injection, and its prepn. method
11/29/2006	CN1286844C Medicinal composition containing angiotensin II receptor antagonist and vitamin B
11/29/2006	CN1286835C Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
11/29/2006	CN1286527C Anti irritability Specificity Igy and its preparation
11/29/2006	CN1286526C Anti-cancer medicine composition
11/29/2006	CN1286524C Use of OPN for treatment and/or prevention of neurological diseases
11/29/2006	CN1286467C Method for producing antibiotic preparation and its application
11/29/2006	CN1286462C Medical preparation for injection
11/29/2006	CN1286456C Luolai compositions useful for the treatment of type-2 synalbumin diabetes pharmaceutical application
11/28/2006	US7142910 Methods of indirectly stimulating the vagus nerve with an electrical field
11/28/2006	US7141610 Using glycol ether to detach retinal tissue
11/28/2006	US7141604 Administering to a patient citalopram or salts to treat hypertension and hypotension
11/28/2006	US7141599 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
11/28/2006	US7141598 Imidazole derivatives, production method thereof and use thereof
11/28/2006	US7141580 activity as prostaglandin E2 receptor antagonists
11/28/2006	US7141578 For treating cancer, cardiovascular, sexual and immune disorders; 3a alpha ,4 beta ,5 alpha ,7 beta ,7a alpha )-4-(Octahydro-5- ethylsulfonamido-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2- (trifluoromethyl)benzonitrile
11/28/2006	US7141576 4-quinazolineamine derivatives; antineoplastic agents; inhibitors of erb family tyrosine kinases and/or epidermal growth factor receptors
11/28/2006	US7141575 Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists
11/28/2006	US7141574 Viral polymerase inhibitors
11/28/2006	US7141572 For therapy of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS
11/28/2006	US7141550 Intra-tumoral administration of IL-12 encoding nucleic acid molecules
11/28/2006	US7141541 Use of peptides
11/28/2006	US7141434 Utilizing an adenosine kinase as a surrogate analyte; methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts
11/28/2006	US7141383 EDG8 receptor, its preparation and use
11/28/2006	US7141365 Methods for diagnosing a mucin production associated disease condition
11/28/2006	US7141252 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation
11/28/2006	US7141251 Pharmacologically active strong acid solutions
11/28/2006	US7141237 Pharmaceutical foam
11/28/2006	US7141045 Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same
11/28/2006	CA2268305C Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
11/28/2006	CA2222311C Use of at least one beta-adrenergic agonist as a p substance antagonist
11/23/2006	WO2006124689A2 Combination therapy
11/23/2006	WO2006124630A2 Compositions and methods for enhancing the efficacy of vaccines
11/23/2006	WO2006123827A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006	WO2006123726A1 Pharmaceutical composition
11/23/2006	WO2006123699A1 Inducer of differentiation of stem cell into osteoblast
11/23/2006	WO2006123644A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF
11/23/2006	WO2006123358A2 Stabilized atorvastatin-containing formulation
11/23/2006	WO2006123279A2 Natural drugs containing calcium and phosphate and apparatus for iontophoretic treatment of osteoporosis
11/23/2006	WO2006122685A1 Compositions for the treatment of psoriasis
11/23/2006	WO2006122472A1 Antithyroid ointment for external use and the preparation thereof
11/23/2006	WO2006122431A1 Triazine compounds and compositions thereof for the treatment of cancers
11/23/2006	WO2006103056A3 Topical product containing betaine for preventing and treating nappy rash
11/23/2006	WO2006084757A3 Combination of ca/mg salt of valsartan with an antidiabetic agent
11/23/2006	WO2006017369A3 Use of a farnesyl transferase inhibitor in the treatment of viral infections
11/23/2006	WO2005074995A3 Combined use of prame inhibitors and hdac inhibitors
11/23/2006	WO2005000224A3 Novel dermatological composition
11/23/2006	US20060265763 Dyrks as modifiersof the apc and axin pathways and methods of use
11/23/2006	US20060264638 Useful in the treatment of chronic and acute pain; 1-[4-dibenzocycloheptyl-4-piperidinyl]-1,3-dihydro-2H-1,3-benzamidazol-2-one;
11/23/2006	US20060264630 Antidiabetic agents; modulate insulin drug resistance
11/23/2006	US20060264517 Methods of reducing microbial resistance to drugs
11/23/2006	US20060264515 Compounds, formulations, and methods for ameliorating telangiectasias
11/23/2006	US20060264510 Antiviral methods and compositions
11/23/2006	US20060264509 Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
11/23/2006	US20060264508 Modulation of ocular growth and myopia by gaba drugs
11/23/2006	US20060264493 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
11/23/2006	US20060264468 Use of substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
11/23/2006	US20060264466 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264465 N-(1-methylpiperidin-4-yl)-N-(4-flourophenylmethyl)-N-'-(4-(2-methylpropyloxy)phenylmethyl)carbamide ; antipsychotic and anti-dyskinetic; use as novel therapeutics, sometimes in conjunction with other therapeutics, for Parkinson's Disease, related human neurodegenerative diseases, and psychosis
11/23/2006	US20060264456 Phosphorus-containing compounds & uses thereof
11/23/2006	US20060264443 Treatment of rheumatoid arthritis
11/23/2006	US20060264436 Method of Treating a Psychotic Disorder
11/23/2006	US20060264434 Chemokine receptor binding heterocyclic compounds
11/23/2006	US20060264409 Ulcerative colitis and Crohn's disease; 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine)
11/23/2006	US20060264390 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
11/23/2006	US20060264389 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
11/23/2006	US20060264363 Inhibition of nerve cell death by inhibiting degradation of shc3, atf6 or crebl1 by htra2 and method of ameliorating neurodegenerative diseases
11/23/2006	US20060264356 Increased or improved bioavailability of the active agents for oral, intracolonic, pulmonary, and other routes of administrations
11/23/2006	US20060263881 Methods of expanding and selecting disease associated T-Cells
11/23/2006	US20060263854 Immunodiagnostic assays using reducing agents
11/23/2006	US20060263820 Delivery of disease control in aquaculture and agriculture using microbes containing bioactive proteins
11/23/2006	US20060263819 Diagnostics and therapeutics for macular degeneration-related disorders
11/23/2006	US20060263801 Methods of high-throughput screening for internalizing antibodies
11/23/2006	US20060263772 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid
11/23/2006	US20060263447 Treating pulmonary disorders with gaseous agent causing repletion of GSNO
11/23/2006	US20060263430 instrument for inducing cytokine and method of inducing cytokine
11/23/2006	US20060263425 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
11/23/2006	US20060263392 Method for treating neovascularization
11/23/2006	US20060263383 Prognostic indicator
11/23/2006	US20060263373 Utilization of an aminopeptidase inhibitor
11/23/2006	US20060263371 Prognostic indicator
11/23/2006	US20060263370 Prognostic indicator
11/23/2006	US20060263347 Lyophilizing an aqueous mixture of a fibrinolytic metalloproteinase, a zinc stabilizer and optionally a bulking agent, in a citric acid or a water soluble citric acid salt buffer and reconstituing said lyophilized composition
11/23/2006	US20060263346 Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds
11/23/2006	US20060263331 Therapeutic use of tumor necrosis factor-alpha mutein
11/23/2006	CA2609814A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006	CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006	CA2608577A1 Confectionery products for the treatment of dry mouth
11/23/2006	CA2608473A1 Combination therapy
11/23/2006	CA2608463A1 Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers
11/23/2006	CA2607472A1 Antipyretic agents against vr1-antagonist-induced increases in body temperature

1 ... 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 ... 1151